NCT00283114 2014-12-18
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
Phase 1 Completed
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Seagen Inc.